Upper Macungie Township Community Fund

Non-profitUnited Statesuppermacfund.org

The Upper Macungie Township Community Fund is a 501(c)(3) nonprofit organization committed to leading, planning, and advancing projects and programs that support residents of Upper Macungie Township in Pennsylvania's Lehigh Valley.

Read more

Its main activities center on inspiring philanthropy, engaging donors and community partners, and raising private resources to fund high-impact initiatives that improve quality of life. The fund's flagship effort supports the development of the Upper Macungie Township Community Lifestyle Center, a large indoor recreational facility in Grange Park featuring turf fields, fitness spaces, meeting rooms, and community programming.

It also aids parks, recreation facilities, and related programs in the township. The organization operates locally within Upper Macungie Township, serving a growing population of about 26,000 residents in a rapidly expanding suburban area with strong economic activity.

Led by a volunteer board of directors that includes community members, township officials, and representatives from founding corporate partners such as Jaindl Family of Companies, Alvin H. Butz Inc., Air Products, and Lehigh Valley Health Network (part of Jefferson Health), the fund functions as an independent entity focused on complementing public resources with private investment. It holds a key position in facilitating community development and wellness initiatives in one of Pennsylvania's fastest-growing townships.

Also known as UMTCF and Upper Macungie Township Community Fund (UMTCF).

Projects Upper Macungie Township Community Fund is involved in

None yet. When a new project in the record names Upper Macungie Township Community Fund as owner, partner or investor, it shows here.

Active projects close to Upper Macungie Township Community Fund

Upper Macungie Township Community Fund in chemical industry news

12 November 2026
Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.